Literature DB >> 26457865

Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.

Antonios Douros1,2, Katja Grabowski1, Ralf Stahlmann1.   

Abstract

INTRODUCTION: Oxazolidinones are synthetic antimicrobials with strong bacteriostatic activity against Gram-positive organisms. Recently, tedizolid phosphate was approved for clinical use becoming the second agent of this class after linezolid available in clinical practice. AREAS COVERED: Oxazolidinone pharmacology including structure-activity relationships, mode of action, pharmacokinetics, drug-drug interactions, and adverse drug reactions is reviewed. Furthermore, bacterial resistance, approved indications, use in paediatric populations, and tuberculosis treatment with oxazolidinones are discussed, and differences in indications and pharmacotoxicological properties between the two approved agents are elucidated. A MEDLINE PubMed search for articles published in English from January 1960 to June 2015 was completed using the terms: oxazolidinone, oxazolidinone-induced toxicity, oxazolidinone pharmacokinetics, serotonin syndrome, oxazolidinone drug-drug interactions, antituberculotic treatment. EXPERT OPINION: Linezolid illustrates an important antimicrobial in several Gram-positive infections especially when methicillin-resistant Staphylococcus aureus strains are involved. Myelosuppression and neuropathy are toxicities of high relevance particularly in case of prolonged treatment periods. The significance of linezolid in the treatment of extensively drug-resistant tuberculosis has to be further investigated. Tedizolid phosphate represents a welcome addition in our anti-infective arsenal, and future research will clarify its role in indications other than the already approved acute bacterial skin infections.

Entities:  

Keywords:  Gram-positive; novel antimicrobials; tuberculosis treatment

Mesh:

Substances:

Year:  2015        PMID: 26457865     DOI: 10.1517/17425255.2015.1098617

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  19 in total

1.  An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.

Authors:  Amit Kaushik; Abigail M Heuer; Drew T Bell; Jeffrey C Culhane; David C Ebner; Nicole Parrish; J Thomas Ippoliti; Gyanu Lamichhane
Journal:  Bioorg Med Chem Lett       Date:  2016-06-09       Impact factor: 2.823

2.  Safety and Tolerability of More than Six Days of Tedizolid Treatment.

Authors:  Mireia Mensa Vendrell; Maria Tasias Pitarch; Miguel Salavert Lletí; Eva Calabuig Muñoz; Laura Morata Ruiz; Genís Castells Lao; Ester López Suñé; Jose Mensa Pueyo; Maria Rosa Oltra Sempere; Maria-Luisa Pedro-Botet Montoya; Valentina Isernia; Esteban Alberto Reynaga Sosa; Leonor Moreno Nuñez; Juan Pasquau Liaño; Sergio Sequera Arquelladas; José Ramón Yuste Ara; Alex Soriano Viladomiu
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.

Authors:  Shaochen Guo; Bin Wang; Lei Fu; Xi Chen; Weiyan Zhang; Haihong Huang; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

Review 4.  A Review of Population Pharmacokinetic Analyses of Linezolid.

Authors:  Enrique Bandín-Vilar; Laura García-Quintanilla; Ana Castro-Balado; Irene Zarra-Ferro; Miguel González-Barcia; Manuel Campos-Toimil; Víctor Mangas-Sanjuan; Cristina Mondelo-García; Anxo Fernández-Ferreiro
Journal:  Clin Pharmacokinet       Date:  2022-06-14       Impact factor: 5.577

5.  Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients.

Authors:  Hitoshi Kawasuji; Yasuhiro Tsuji; Chika Ogami; Makito Kaneda; Yushi Murai; Kou Kimoto; Akitoshi Ueno; Yuki Miyajima; Yasutaka Fukui; Ippei Sakamaki; Yoshihiro Yamamoto
Journal:  Antibiotics (Basel)       Date:  2021-04-26

Review 6.  Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.

Authors:  Olivia Ferrández; Olatz Urbina; Santiago Grau
Journal:  Drug Des Devel Ther       Date:  2016-12-22       Impact factor: 4.162

7.  Potential Drug-Drug Interactions with Antimicrobials in Hospitalized Patients: A Multicenter Point-Prevalence Study.

Authors:  Ferit Kuscu; Aslihan Ulu; Ayse S Inal; Bedia M Suntur; Hande Aydemir; Serdar Gul; Kenan Ecemis; Suheyla Komur; Behice Kurtaran; Ozlem Ozkan Kuscu; Yesim Tasova
Journal:  Med Sci Monit       Date:  2018-06-20

Review 8.  Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.

Authors:  Darrell McBride; Tamara Krekel; Kevin Hsueh; Michael J Durkin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-16       Impact factor: 4.481

9.  Identification of the Multiresistance Gene poxtA in Oxazolidinone-Susceptible Staphylococcus haemolyticus and Staphylococcus saprophyticus of Pig and Feed Origins.

Authors:  Lin Chen; Jian-Xin Hu; Chang Liu; Jiao Liu; Zhen-Bao Ma; Zi-Yun Tang; Ya-Fei Li; Zhen-Ling Zeng
Journal:  Pathogens       Date:  2021-05-14

10.  Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study.

Authors:  Tristan Ferry; Anne Conrad; Eric Senneville; Sandrine Roux; Céline Dupieux-Chabert; Aurélien Dinh; Sébastien Lustig; Sylvain Goutelle; Thomas Briot; Truong-Thanh Pham; Florent Valour
Journal:  Open Forum Infect Dis       Date:  2021-07-02       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.